Similar articles

• Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase.

  Warren MP. Warren MP. Evid Based Med. 2014 Jun;19(3):105. doi: 10.1136/eb-2013-101656. Epub 2014 Feb 3. Evid Based Med. 2014. PMID: 24492931 No abstract available.
• Hormone therapy use and outcomes in the Women's Health Initiative trials.

  Roehm E. Roehm E. JAMA. 2014 Jan 22-29;311(4):417. doi: 10.1001/jama.2013.285154. JAMA. 2014. PMID: 24449322 No abstract available.
• Hormone therapy use and outcomes in the Women's Health Initiative trials--reply.

  Manson JE, Chlebowski RT, Aragaki AK. Manson JE, et al. JAMA. 2014 Jan 22-29;311(4):417-8. doi: 10.1001/jama.2013.285163. JAMA. 2014. PMID: 24449323 No abstract available.
• [Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate].

  Ortmann J, Traupe T, Vetter W, Barton M. Ortmann J, et al. Praxis (Bern 1994). 2004 May 19;93(21):904-14. doi: 10.1024/0369-8394.93.21.904. Praxis (Bern 1994). 2004. PMID: 15216975 Review. German.
• New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

  Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT. Modena MG, et al. Maturitas. 2005 Sep 16;52(1):1-10. doi: 10.1016/j.maturitas.2005.05.003. Maturitas. 2005. PMID: 15963666 Review.